DescriptionProduct Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).Transfection Reagent for Astrocytes (Primary Astrocyte Cells, Astroglia)Proprietary cationic lipids formulationHigh transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNAEffective and robust intracellular deliveryKit includes Transfection Enhancer reagentProduces consistent results, lot-to-lot, plate-to-plate, and well-to-wellWork in the presence of serumA proven reagent for establishing stable cell linesOptimized transfection protocols are adapted for use with both standard & reverse transfection methodsDownload in vitro Astrocyte transfection protocol: [PDF]Download Astrocyte CRISPR/Cas9 transfection protocol: [PDF]Download PowerPoint presentation for Astrocyte cells transfection kit: [PPT]Developed and manufactured by Altogen BiosystemsTransfection Efficiency:Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.Transfection Protocol and MSDS:Download Altogen Biosystems Astrocyte Transfection Protocol: [PDF]Download MSDS: [PDF]Astrocyte Cells (Primary Astrocytes and Astroglia):The human brain comprises two major cell types: neurons and glia. Neurons are responsible for transmitting nerve signals while glia safeguard neurons. Astrocytes, a sort of glial cells, make over 50% of all brain cells. In the event of any distress to the Central Nervous System (CNS), a process called gliosis is triggered. Gliosis involves the rapid differentiation of glial cells to provide mechanical support to neurons. However, excessive gliosis is symptomatic of various forms of brain cancer. Per the study published in the January 2016 issue of Tumor Biology, astrocytes play an important role in controlling the environment around a tumor. Astrocytes retard the detection of cancer cells by the immune system and help enhance their proliferation. Preclinical research targeting astrocytes can provide valuable insight into molecular pathways that can curb tumors. Transfection is a well-regarded technique to conduct preclinical research in many different cells, including astrocytes.Astrocytes are star-shaped glial cells in the brain and spinal cord. Astrocytes are supportive cells, and their functions include biochemical support of endothelial cells, which form the blood-brain barrier, providing nutrients to the nerve tissue, extracellular K+ level regulation, neurotransmitters removal, and helping repair the brain and spinal cord following traumatic injuries. They are also dependent on myelination and synapses formation. Many primary astrocytes express the intermediate filament glial fibrillary acidic protein or GFAP. Research indicates that astrocytes communicate with neurons through the release of gliotransmitters via a calcium ion process. There are three types of astrocytes in the central nervous system: fibrous, protoplasmic and radial. It is believed astrocytes cell bodies are separate and do not overlap.Astrocytes, also known as astroglia, are cells in living organisms that make up parts of the nervous system, particularly in the brain and spinal cord. They work with the body’s natural response to trauma in the brain and spinal cord, by repairing and providing nutrients to affected areas. Because of this, astrocytes may be useful in the study of specific medical treatments for patients suffering from spinal cord injuries. These cells are crucial to research in the field of neuroscience.Primary cell cultures are used in biological and gene therapy studies and serve as valuable model systems that may more accurately represent the biology of healthy cells. Many cultured cell lines, as well as the majority of primary cell cultures, can be transfected with exogenous nucleic acids when appropriate transfection approaches are employed. Since the majority of transfection methods causes significant toxicity in primary cell cultures, optimizing this procedure, specifically the protocol and reagents to be utilized, is essential for developing an effective transfection strategies for a given cell type. ALTOGEN® Kits for primary cells and sensitive cell lines have been designed to have significantly lower cytotoxicity than other alternatives.Data:Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into actrocyte cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=3).Figure 2. Protein expression of Lamin A/C in Astrocyte cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into Astrocyte cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.Selected Astrocyte Transfection Reagent product citations:Journal of Neuroscience. 2013 33(44). Foxo3a Transcriptionally Upregulates AQP4 and Induces … Kapoor et al [PDF]Mol Cell Biol. 2013 33(7). SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation … Madan et al [PDF] Request a Quote forAstrocyte Transfection ReagentAltogen Biosystems:Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life sciences and cancer research. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits (animal transfection): 1) Tissue-targeted reagents (delivery of proteins, DNA, and RNA into liver, pancreas, or kidney tissues), and 2) Broad range in vivo biodistribution reagents (PEG-Liposome based reagent, Nanoparticle-based in vivo reagent, Lipid-based transfection kit, and Polymer-based kit). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.Altogen Research Services:Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com). Volume Options:0.5 ml (Catalog #1711)1.5 ml (Catalog #1712)1.5 ml CRISPR (Catalog #2110)8.0 ml (Catalog #1713)

Altogen Biosystems全国代理部分产品列表：

货号	产品	规格	价格（美元）
5030
1703	A204 Transfection Reagent (Rhabdomyosarcoma)	0.5ml	170
1704	A204 Transfection Reagent (Rhabdomyosarcoma)	1.5ml	348 窗体顶端 窗体底端
2101	A204 Transfection Reagent (Rhabdomyosarcoma)	1.5ml CRISPR	548 窗体顶端 窗体底端
7018	A204 Transfection Reagent (Rhabdomyosarcoma)	8.0ml	1044 窗体顶端 窗体底端
1167	A375 Cells Transfection Reagent (CRL-1619)	0.5ml	195
1168	A375 Cells Transfection Reagent (CRL-1620)	1.5ml	427
2102	A375 Cells Transfection Reagent (CRL-1621)	1.5ml CRISPR	627
1169	A375 Cells Transfection Reagent (CRL-1622)	8.0ml	1281
5030	Nanoparticle In Vivo Transfection Reagent	0.5 ml - 10 injections	445
5010	LIPID In Vivo Transfection Reagent	0.5 ml - 10 injections	405
5040	PEG-Liposome In Vivo Transfection Reagent	0.5 ml - 10 injections	465
5020	POLYMER In Vivo Transfection Reagent	0.5 ml - 10 injections	425
5050	Pancreas In Vivo Transfection Kit	0.5 ml - 10 injections	495
5060	Liver In Vivo Transfection Kit	0.5 ml - 10 injections	495
5070	Kidney In Vivo Transfection Kit	0.5 ml - 10 injections	495
1721	BMS2 Transfection Reagent (Bone Marrow Cells)	0.5 ml	231
6345	C6 Transfection Reagent (Glioma Cells, CCL-107)	0.5 ml	199
6803	DLD-1 Transfection Reagent (Colon Cancer, CCL-221)	0.5 ml	201
1775	HUH-7 Transfection Reagent (Liver Cancer Cells)	0.5 ml	179